Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02200354 | The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab | terminated | Phase 2 | 20 | Kobe City General HospitalOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02322281 | TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | terminated | Phase 3 | 149 | Clovis Oncology, Inc.INDUSTRY | 10 | Aug 14, 2019 |
| clinicaltrials |
| NCT01822496 | Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | terminated | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2019 | clinicaltrials |
| NCT02109016 | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations | terminated | Phase 2 | 18 | Clovis Oncology, Inc.INDUSTRY | 5 | Jul 29, 2019 | clinicaltrials |
| NCT01646125 | An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | terminated | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 24, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02431169 | Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression | terminated | — | 5 | Washington University School of MedicineOTHER | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | terminated | Phase 1 / Phase 2 | 13 | PrECOG, LLC.OTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT02630186 | A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC | terminated | Phase 1 / Phase 2 | 3 | Clovis Oncology, Inc.INDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT00714246 | Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 6 | Milton S. Hershey Medical CenterOTHER | 1 | Jun 24, 2019 | clinicaltrials |
| NCT00685750 | Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma | terminated | N/A | 88 | GlaxoSmithKlineINDUSTRY | 5 | Jun 20, 2019 | clinicaltrials |
| NCT02410382 | Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer | terminated | Phase 2 | 79 | University of ArizonaOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT02186301 | TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy(EGFR) | terminated | Phase 2 / Phase 3 | 100 | Clovis Oncology, Inc.INDUSTRY | 7 | May 7, 2019 | clinicaltrials |
| NCT02080078 | A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline | terminated | Phase 1 | 15 | AHS Cancer Control AlbertaOTHER | 1 | May 3, 2019 | clinicaltrials |
| NCT00568906 | Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma | terminated | — | 129 | Stanford UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT02775006 | Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma | terminated | Phase 3 | 45 | The Netherlands Cancer InstituteOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT00793208 | Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 1 | Theresa Whiteside, PhDOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT02556593 | IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases | terminated | Phase 2 | 12 | Sun Yat-sen UniversityOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT02751385 | Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 | 2 | Boehringer IngelheimINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT00153842 | A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer | terminated | Phase 1 / Phase 2 | 33 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT03172988 | Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery | terminated | Phase 4 | 126 | Peking University First HospitalOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02846792 | Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 5 | University of WashingtonOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT02483416 | Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance | terminated | — | 30 | Boehringer IngelheimINDUSTRY | 1 | Mar 1, 2019 | clinicaltrials |
| NCT01210378 | Nitroglycerin in Non-small Cell Lung Cancer(Nitroglycerin) | terminated | Phase 2 | 47 | Maastricht Radiation OncologyOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02409355 | A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | terminated | Phase 3 | 8 | Hoffmann-La RocheINDUSTRY | 14 | Feb 15, 2019 | clinicaltrials |
| NCT02346370 | A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC(PRIMAL) | terminated | Phase 1 | 16 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | terminated | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT01207726 | Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery | terminated | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Feb 5, 2019 | clinicaltrials |
| NCT00769600 | Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC | terminated | Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 1, 2019 | clinicaltrials |
| NCT02162537 | Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases(METAL2) | terminated | Phase 3 | 95 | Centre Hospitalier Intercommunal CreteilOTHER | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02258607 | Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase | terminated | Phase 1 | 21 | Sierra Oncology LLC - a GSK companyINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT01891669 | A Study Of PF-06263507 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 26 | PfizerINDUSTRY | 1 | Jan 9, 2019 | clinicaltrials |
| NCT02353741 | Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC(CERTAIN) | terminated | Phase 2 | 10 | Xinqiao Hospital of ChongqingOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT01578551 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. | terminated | Phase 2 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00924209 | A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer | terminated | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 2 | Nov 30, 2018 | clinicaltrials |
| NCT00745732 | Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT02737709 | Paclitaxel Detection in NSCLC Treated With TC Regimen | terminated | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT00735878 | Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer | terminated | Phase 1 / Phase 2 | 20 | Konstantin DragnevOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT02580708 | Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 7 | Clovis Oncology, Inc.INDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00260598 | LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer | terminated | Phase 2 | 142 | University of PittsburghOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02055170 | Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer | terminated | Phase 2 | 4 | CancerCare ManitobaOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT01058759 | Taxotere-Enoxaparin-(ENOXA)-Study | terminated | Phase 3 | 14 | Hannover Medical SchoolOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT00200382 | Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer | terminated | Phase 2 | 27 | Rasim GucalpOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01028612 | Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer > 3.5 cm in Size(NSCLC) | terminated | N/A | 1 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT01935947 | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2018 | clinicaltrials |
| NCT02671045 | Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer | terminated | — | 649 | Cota Inc.INDUSTRY | 1 | Jul 20, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2019source: clinicaltrials